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Background: Amifostine (WR-2721, delivered as Ethyol®) is a phosphorylated aminothiol compound clinically used
in addition to cis-platinum to reduce the toxic side effects of therapeutic treatment on normal cells without
reducing their efficacy on tumour cells. Its mechanism of action is attributed to the free radical scavenging
properties of its active dephosphorylated metabolite WR-1065. However, amifostine has also been described as a
potent hypoxia-mimetic compound and as a strong p53 inducer; both effects are known to potently modulate
vascular endothelial growth factor (VEGF-A) expression. The angiogenic properties of this drug have not been
clearly defined.
Methods: Cancer cell lines and endothelial cells were used in culture and treated with Amifostine in order to
study (i) the expression of angiogenesis related genes and proteins and (ii) the effects of the drug on VEGF-A
induced in vitro angiogenesis.
Results: We demonstrated that the treatment of several human cancer cell lines with therapeutical doses of
WR-1065 led to a strong induction of different VEGF-A mRNA isoforms independently of HIF-1a. VEGF-A induction
by WR-1065 depends on the activation of the eIF2alpha/ATF4 pathway. This up-regulation of VEGF-A mRNA was
accompanied by an increased secretion of VEGF-A proteins fully active in stimulating vascular endothelial cells (EC).
Nevertheless, direct treatment of EC with amifostine impaired their ability to respond to exogenous VEGF-A, an
effect that correlated to the down-regulation of VEGFR-2 expression, to the reduction in cell surface binding of
VEGF-A and to the decreased phosphorylation of the downstream p42/44 kinases.
Conclusions: Taken together, our results indicate that amifostine treatment modulates tumour angiogenesis by
two apparently opposite mechanisms - the increased VEGF-A expression by tumour cells and the inhibition of EC
capacity to respond to VEGF-A stimulation.
Background
First developed for its cytoprotective properties against
radiation, amifostine is now approved by the US Food
and Drug Administration for clinical use as a cytopro-
tector in several anti-cancer therapies [1]. Amifostine,
also called Ethyol®, is a phosphorylated aminothiol (WR-
2721). Its intracellular activity relies on its dephosphory-
lation by membrane bound alkaline phosphatase [2],
thus producing the free thiol WR-1065. WR-1065 acts
as a free radical scavenger and is considered to be the
effective cytoprotector, affording protection against the
toxic side effects of both chemotherapeutic agents and
ionizing radiations [3-5]. This cytoprotection has been
shown to be mostly effective on normal cells and does
not interfere with the efficacy of anticancer treatment in
tumours [6]. This selective effect on normal cells was
attributed, in part, to the acidic microenvironment
found in numerous tumour tissues, which decreases the
rate of prodrug activation by the alkaline phosphatase
and also to a lower expression of the enzyme in the
tumour endothelium [2]. Abnormal tumour vasculature
is also thought to lower the drug’s access to tumour * Correspondence: s.north@angio.u-bordeaux1.fr
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cer cells, even at a lower rate, and has often been
described as enhancing the antitumour effects of che-
motherapeutic agents and ionizing radiations [4,7,8].
This latter property, albeit not clearly understood, may
depend on the activation of key regulatory proteins in
cancer cells, such as the tumour-suppressive p53 pro-
tein, which is activated by amifostine and can block cell
proliferation in p53 WT tumour cells, or enhance apop-
tosis due to chemotherapeutic agents in p53 deficient-
tumour cells [9-12]. Amifostine has also been reported
to act as a hypoxia-mimetic compound able to promote
hypoxia-inducible factor (HIF)-1a accumulation both
in vitro and in vivo [13]. HIF-1a is a major stress regulator
induced by cancer cells in response to ischaemia during
tumour development. Stabilized by hypoxia, HIF-1a het-
erodimerizes with the HIF-1b subunit and activates the
transcription of different sets of genes involved in numer-
ous cellular processes including metabolism, apoptosis
and angiogenesis [14]. The most prominent pro-angio-
genic factor activated by HIF in response to hypoxia is the
vascular endothelial growth factor (VEGF-A). Cancer cells
secrete VEGF-A as different isoforms that diffuse through
the tumour microenvironment and bind to the specific
transmembrane receptors VEGFR1, VEGFR-2 and neuro-
pilin-1, mainly located on vascular endothelial cells (ECs)
[15,16]. VEGFR-2 is believed to mediate most of the para-
crine effects of VEGF-A known to promote angiogenesis:
vascular permeability, EC proliferation, migration, survival
and association in micro-capillary structures [17]. More-
over, VEGFR-2 has been recently implicated in VEGF-A
autocrine loops in EC, that seem to be essential to their
survival and to the maintenance of the differentiated state
of blood vessels [18].
Induction of VEGF-A expression also occurs under
different cellular stresses through HIF-1- independent
pathways [19-22]. As an example, VEGF-A expression
can be activated by the inositol requiring enzyme 1
(IRE1)-dependent pathway, a branch of the unfolded
protein response (UPR), in response to hypoxia or glu-
cose deprivation [21]. Reductive agents such as dithio-
threitol (DTT) and homocysteine are also potent
inducers of the UPR and of an activating transcription
factor 4 (ATF4)-mediated transcription of the VEGF-A
gene [23-25]. Besides their effects on VEGF-A expres-
sion, thiolic-reducing agents may impair VEGF-A signal-
ling on EC via their free radical scavenging properties.
Indeed, these compounds may interfere with the pro-
duction of reactive oxygen species (ROS) which is
necessary to the phosphorylation of extracellular signal-
regulated kinase (ERK) downstream of VEGFR-2, and to
the mitotic response of EC [26,27]. These effects may
significantly impact tumour growth and metastasis
[28-31].
Despite some reports on HIF expression, the effects of
amifostine on angiogenesis have been poorly studied and
the results found in the literature are often controversial.
Using the developmental angiogenesis model of the
chorio-allantoic membrane (CAM), both pro- and anti-
angiogenic effects have been reported [32,33]. The anti-
angiogenic effect was attributed to the ability of amifostine
to modify the redox status of EC in vitro. However, a pro-
liferating effect of the drug was concomitantly observed
[34]. Moreover, Grdina et al. described an anti-metastatic
effect of amifostine in mice developing Sa-NH sarcoma, in
association with high serum levels of the angiogenesis
inhibitor angiostatin. This observation suggests that ami-
fostine could have anti-angiogenic properties [35,36]. Little
is written about the effects of amifostine on VEGF-A
expression in these studies and nothing in relation to
VEGF-A expression in tumour cells.
In order to better characterize the potential effects of
amifostine on tumour angiogenesis, we undertook a sys-
tematic study to analyse its effect on VEGF-A expres-
sion, production and activity on human cancer and EC.
Methods
Reagents
We used culture media obtained from Invitrogen (CA,
USA) and Cambrex (MD, USA). Fetal bovine serum
(FBS) was obtained from Biowest (Nuaillé, France) and
was heat-inactivated before use. Growth Factor Reduced
Matrigel was obtained from Becton Dickinson Bios-
ciences (NJ, USA). Bovine serum albumine (BSA), cell-
culture grade gelatin, fibronectin, DTT, protamine sul-
phate, aminoguanidine and amifostine (WR-2721) were
purchased from the Sigma Chemical Co (MO, USA).
The metabolically active form of amifostine (WR-1065)
was synthesized by Dr M. Zanda (CNR, Milan, Italy).
The VEGF-A neutralizing polyclonal antibody was
obtained from R&D Systems (Minneapolis, USA). Pri-
mary antibodies against human HIF-2a and b-actin
were obtained from Santa Cruz Biotechnology (CA,
USA); anti-human Ku80 from Serotec (Oxford, UK);
anti- human HIF-1a from BD Transduction Labora-
tories (Le Pont de Claix, France); anti-VEGFR-2 from
ReliaTech (Braunschweig, Germany); anti- phospho-
eIF2a (Ser51), anti-eIF2a and antibodies to p42/44 and
their phosphorylated counterparts from Cell Signaling
Technology (MA, USA). Primers for ATF4 were as
described by Namba et al. [37]. Primers for GADD34,
CHOP, EDEM and BIP were as previously described
[21]. Other primer used for mRNA expression analysis,
were reported in Additional File 1 (Table S1). All pri-
mers were obtained from Proligo (Paris, France).
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Human mammary carcinoma cells MCF7 and colon car-
cinoma HCT116 cells were a gift from Dr P Hainaut
(International Agency for Research on Cancer, Lyon,
France). MCF7 cells and U87 human glioma cells
( A T C C ,H T B - 1 4 )w e r eg r o w ni nD u l b e c c o ’s modified
eagle medium (DMEM) supplemented with 10% FBS.
HCT116 cells were grown in McCoy medium, 10% FBS.
Human umbilical EC (HUVEC; Clonetics, CA, USA)
were propagated up to eight passages on a 0.2% gelatine
matrix in endothelial growth medium (EGM-2; Bulletkit,
Walkersville, USA). Treatments of tumour cells with
amifostine were performed in the presence of 4 mM
aminoguanidine (AG), as previously described [10]. AG
prevents the catabolization of amifostine by FBS Cu-
dependant amine-oxydases into cytotoxic compounds
[38]. Amifostine treatments on HUVEC were performed
without AG. Hypoxic conditions were obtained at 3%
O2 in a Heraeus incubator BB-6060.
Lentiviral vector constructs and MCF7 transduction
MCF7 were transduced using lentivectors expressing the
fluorescent marker E-GFP and containing short hairpin
RNA sequences against HIF-1a [HIF-1a.small hairpin
(sh)RNA] or red fluorescent protein (RFP.shRNA) as
described [39]. For transduction, MCF7 cells (5.10
4 cells
per well in a 24-multiwell plate) were incubated for
24 h in complete medium. Cells were then incubated
with viral supernatants from 293T cells for 24 h at 37°C
in the presence of protamine sulphate. Transduced cells
were sorted out 5 days post-transduction by cytofluori-
metry. Enhanced green fluorescent protein (E-GFP)
positive cells were used for the experiments.
ATF4 RNA interference and transient transfection of MCF7
Small interfering RNAs (siRNAs) were purchased from
Eurogentec (Liège, Belgiu m ) .T h es e q u e n c eo ft h e
ATF4-targeting SiRNA (SiATF4) was as previously
described [40]. A SiATF4 mutated in three nucleotides
served as control (SiMUT, 51). Cells at a 50% density
were transfected with 250 nM of SiRNA in OptiMEM
using Lipofectamine Plus (Invitrogen, CA, USA). After
24 h, cells were either treated or not treated with ami-
fostine; cells and supernatants were then collected for
RNA isolation and protein analysis.
VEGF-A enzyme-linked immunoadsorbent assay (ELISA)
Cells at 60% confluence were grown in 5-cm diameter
dishes for the indicated period of time. VEGF-A concen-
tration was measured in cell-conditioned media using a
commercial VEGF-A ELISA kit (R&D Systems, Minnea-
polis, USA). Assays were performed in triplicate and
calibration curves were obtained using human recombi-
nant VEGF-A. The results were analysed using the
Softmax Pro4.0 software (Molecular Devices Corpora-
tion, CA, USA). Cells were counted using a cell counter
(Coulter, Becton Dickinson, NJ, USA).
Wst-1 metabolic assay
The paracrine effect of amifostine was assayed as fol-
lows. MCF7 cells were first incubated for 48 h, either in
the presence of AG alone or with both AG- and amifos-
tine. Conditioned media (CM) in these conditions were
dialysed at 4°C in order to remove the two chemicals.
HUVEC grown in 96-multiwell plates to 80% confluence
were then starved for 4 h in DMEM without fetal calf
serum (FCS) and incubated for 16 h in the presence of
CM. Wst-1 assays (Roche Applied Science, IN, USA)
were then performed as follow: Wst-1 reagent was
added to the cell medium after a 12 h incubation with
CM and absorbance was read 4 h later at 440 nm using
a spectrophotometer (Molecular Devices Corporation).
Results were analysed using the Softmax Pro 4.0 soft-
ware (Molecular Devices Corporation). The assay was
performed in triplicates. In similar experiments, CM
were pre-incubated for 45 min at 37°C with a VEGF-A
neutralizing antibody or with an irrelevant anti-ß-actin
antibody, prior to addition to HUVEC.
Polymerase chain reaction analysis (PCR)
Reverse transcription (RT) were performed as previously
described [39]. A semi-quantitative analysis of VEGF-A
was performed by co-amplifying VEGF-A and b-actin in
a Thermal Cycler (Eppendorf AG, Hamburg, Germany)
at 94°C for 40 s, 59°C for 30 s, 72°C for 50 s, throughout
35 cycles, with a final elongation step of 3 min at 72°C.
Real time quantitative PCR (Q-PCR) analyses were per-
formed using the MX3000p thermocycler (Stratagene,
CA, USA) and the SYBRgreen dye (ABgene, Epsom,
UK) methodology. The relative abundance of transcripts
was calculated by using a-tubulin or b-actin as
standards.
Immunoblot analysis
MCF7 cells and HUVEC were grown up to the subcon-
fluence in 10 cm diameter dishes. HUVEC were starved
for 24 h in EBM-2 medium, 2% FCS prior to treatments.
Treatments were then performed in fresh medium
(EBM-2 for HUVEC, complete culture medium for
MCF7) and total protein extracts were collected on ice
at different time points with an electrophoretic mobility
shift assay buffer-B [11] for HIF and mitogen activated
protein kinase analysis or as described by Drogat et al.
for eIF-2a analysis [22]. Forty to fifty micrograms of
proteins were separated in SDS-PAGE gels and trans-
ferred to a 0.4 μm nitrocellulose membrane (Schleicher
& Schuell, Dassel, Germany). Proteins of interest were
detected using specific primary antibodies (see figure
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horseradish peroxidase (DAKO SA, Glostrup, Denmark).
Blots were revealed using the enhanced chemilumines-
cence +reagent (Amersham Pharma Biotech, NJ, USA)
followed by radioautography or direct quantification of
chemiluminescence (Fujifilm LAS-3000).
VEGF-A radioligand binding studies
VEGF-A165 was radio-labelled as previously described
[41] to a specific activity ranging from 20,000 to 100,000
cpm/ng. HUVEC were seeded at 7000 cells/cm2 in six-
well plates, cultured for 2 days in EGM-2 and starved
for 24 h in 2% FBS-containing EBM-2 prior to a 12 h-
incubation in the presence, or not, of 1 mM WR-1065.
T h ep l a t e sw e r ew a s h e do n c ew i t hp h o s p h a t eb u f f e r e d
saline (PBS) and the cells were incubated for 2 h at 4°C
with 125I-VEGF-A in DMEM, 20 mM HEPES, 0.2%
gelatine. They were rinsed three times in PBS and finally
solubilized at room temperature in a solution containing
2% Triton X-100, 10% glycerol and 1 mg/mL BSA.
Total cell lysates were counted for radioactivity using a
Kontron MR 250 gamma-counter. Each value reported
in the graph was the mean of duplicate determinations.
Unspecific binding was defined as the amount of radio-
activity bound in the presence of 20 μg/mL protamine
sulphate, which gave results similar to the use of a 100-
fold excess of VEGF-A. The experiments were repeated
three times with similar results. Binding data were ana-
lysed using the GraphPad Prism 4.0 software.
Transwell cell migration assays
HUVEC cell migration was measured using 24-well-
Transwell plates (Becton Dickinson Labware, Le Pont de
Claix, France). Prior to cell seeding, inserts (8-μmp o r e
size) were precoated overnight at 4°C on the lower side
using 10 μg/mL fibronectin in PBS. Membranes were
then blocked 1 h at room temperature with 1% heat-inac-
tivated BSA. HUVEC (10
5 cells per well) were seeded in
the upper compartment and allowed to migrate for 7 h
throughout the membranes in DMEM containing 0.5%
FBS and 0.1% BSA and in the presence of different con-
centrations of WR-1065. VEGF-A (10 ng/mL) was added
in the lower compartment as chemo-attractant. After
migration, cells that had migrated were fixed and stained
in a solution containing 30% methanol, 10% acetic acid
and 0.1% Coomassie Blue. The extent of cell migration
was analysed by counting cells in at least six random
fields per Transwell filter using the LUCIA image analysis
software (Laboratory Imaging, Praha, Czech Republic).
Results are from three independent experiments.
Matrigel tube formation assays
Amifostine was tested for its ability to modulate
endothelial cell differentiation into tube-like structures
using a Matrigel surface assay. Cells (2 × 10
5 cells/mL
of Growth Factor Reduced Matrigel, BD Biosciences,
MA, USA) were seeded in EBM-2 medium supplemen-
ted with 0.2% FBS and 1% L-glutamine and allowed to
adhere for 1 h. Media were then replaced by EBM-2
enriched with 0.5% FBS, containing increasing concen-
trations of WR-1065 with or without 10 mg/mL of
VEGF-A. Cells were then incubated for 3 h at 37°C.
Total length of tube-like structures was assessed using
the LUCIA image analysis software. Results shown are
representative of three independent experiments. Each
data point is the mean of six randomly chosen fields.
Statistics
Statistical analysis of data was performed using the
paired Student’s t test P value (*P < 0.05; **P < 0.01).
Results
Amifostine treatment induces VEGF-A expression
in cancer cell lines
The potential effects of the cytoprotective drug amifos-
tine on the vascular bed still remains unclear and con-
troversial. In order to better characterize the
angiogenesis-related effects of this molecule, we ana-
lysed the effects of its dephosphorylated active form
(WR-1065) on the mRNA expression of VEGF-A, a
growth factor that plays a major role in tumour
angiogenesis.
Three human tumour cell lines from different tissue ori-
gins (U87 glioma cells, MCF7 breast carcinoma cells and
HCT116 colon carcinoma cells) were treated with increas-
ing amounts of WR-1065, surrounding 1 mM, which is a
dose corresponding to the measured concentration of the
drug in tissues of animal models [8,42]. Total VEGF-A
mRNA level was determined by quantitative PCR
(Q-PCR) and its different isoforms were distinguished by
semi-QPCR. As shown in Figure 1A, WR-1065 treatment
induces the accumulation of VEGF-A mRNA in a dose-
dependent manner in all cell types. This effect was
mostly observed for transcripts that correspond to the two
diffusible isoforms (VEGF121, 165) of the growth factor
(Figure 1B). As determined for MCF7 cells, VEGF-A
mRNA increase is accompanied by a significant release of
VEGF-A protein in the culture medium (Figure 1C).
These results suggest a potential pro-angiogenic effect of
amifostine.
VEGF-A mRNA accumulation in response to WR-1065 is
independent of HIF
HIF-1a and HIF-2a are involved in the transactivation
of VEGF-A gene in response to hypoxia [43] and ami-
fostine has been described as a potent hypoxia-mimetic
compound that could activate HIF-1a both in vitro and
in vivo [13]. Therefore, we analysed by Western Blot the
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factors HIF-1a and HIF-2a in MCF7 cells treated with
1 mM WR-1065. As shown in Figure 2A, WR-1065
treatment did not lead to the accumulation of either
HIF-1a or HIF-2a in treated cells, whereas a strong
increase in HIF-1a was observed in cells subjected to
low oxygen concentration (3% instead of 20%). Consis-
tently, 1 or 2 mM WR-1065 failed to induce any nuclear
translocation of HIF-1a whereas lowering oxygen led to
a significant increase of HIF-1a in the nucleus (Addi-
tional File 2, Figure S1).
We then measured the mRNA level of two representa-
tive HIF-1a-dependent genes, namely HK2, GLUT1.A s
expected, expression of these genes was strongly
increased under low oxygen conditions (3% O2 Figure
2B). In comparison, their expression was significantly
repressed (≈ 50%) in response to WR-1065 treatment,
which suggest an HIF-1a-independent effect of WR-
1065 on VEGF-A. In order to definitively exclude an
HIF-1-dependent activationo fV E G F - Ab ya m i f o s t i n e ,
we abolished HIF-1a protein expression by stably
expressing an shRNA directed against the mRNA of
HIF-1a [39]. MCF7 cells were then treated with WR-
1065 or subjected to low oxygen conditions (3%). Under
low level of oxygen (3%), shRNA.HIF but not shRNA.
RFP (Red Fluorescent Protein), led to a strong inhibition
of both HIF-1a protein (90%, Figure 2C) and VEGF-A
mRNA accumulation (50%, Figure 2D). In response to
WR1065 treatment, knock down of HIF-1a did not sig-
n i f i c a n t l ym o d i f yt h ei n c r e a s eo fV E G F - Am R N A
expression. Altogether, these results indicate that the
accumulation of VEGF-A mRNA in WR-1065-treated
cells does not depend on HIF-1a activation.
Amifostine activates the eIF2a/ATF4 triggering pathway
in cancer cells
VEGF-A mRNA induction through HIF-1-independent
signalling pathways has already been described in
response to a variety of cellular stresses, including the
cell response to the accumulation of mis/unfolded pro-
teins (UPR). Since WR-1065 is a thiol reducing agent,
we questioned its effect on the UPR triggering pathways.
We first analysed the expression of the UPR-target
genes BiP, EDEM, GADD34 and CHOP in cells treated
with WR-1065. As shown in Figure 3A, the expression
of the IRE1-dependent genes EDEM and BIP were
slightly (twofold) increased under these conditions. Con-
sistently, the splicing of the XBP1 transcript, another
hallmark of IRE1 activation, was neither observed in
MCF7 nor in U87 cells treated with WR-1065 (Addi-
tional File 3, Figure S2). This confirms that IRE1 was
not significantly activated by amifostine. Besides,
GADD34 and CHOP genes were highly up-regulated
(10- to 13-fold) in response to WR-1065 treatment,
Figure 1 Amifostine enhances vascular endothelial growth
factor A (VEGF-A) mRNA and protein expression in cancer cells.
MCF7 and HCT116 carcinoma cells, as well as U87 glioma cells, were
grown up to 70% confluence in 10-cm culture dishes. Cells were
then incubated in freshly added complete medium under classical
conditions of oxygen (NT, 20% 02) or low oxygen conditions (LO,
low O2,3 %0 2), or in the presence of the indicated concentrations
of WR-1065 under 20% of oxygen. (A) Amifostine increases VEGF-A
mRNA levels in U87, MCF7 and HCT116 cells. Following a 16-h
(MCF7 cells, grey bars) or a 24-h (HCT116 cells, white bars; U87 cells,
black bars) incubation time, total mRNA was isolated. Expression of
VEGF-A mRNA in cells was measured by quantitative polymerase
chain reaction using primers amplifying all the VEGF-A isoforms.
Histogram values represent the level of expression of all VEGF-A
splice variants, normalized to a-tubulin. Results are the mean values
± standard error of mean of three independent experiments. (B)
Amifostine increases specific VEGF-A mRNA isoforms. Shown is a
representative gel electrophoresis pattern of the different VEGF-A
splice variants in U87, MCF7 and HCT116 cells, b-actin being used as
standard. (C) Amifostine increases VEGF-A protein secretion by
MCF7 cells. Cells were treated up to 2 days in complete medium,
and conditioned media were collected after 24 h, 36 h and 48 h of
treatment. VEGF-A protein secretion was measured by ELISA using
supernatants of cells grown under low levels of oxygen (3% O2,) or
20% of oxygen, and of cells treated with 1 mM WR-1065 in the
presence of aminoguanidine (AG) or with AG alone. Results shown
are representative of three independent experiments done in
triplicates.
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factor (HIF). MCF7 cells were incubated in complete medium with WR-1065 in the presence of aminoguanidine (AG) or were subjected to low
levels of oxygen (3% 02,). (A) Amifostine treatment does not lead to any accumulation of HIF proteins. Cells were treated for 6 h under 20% of
oxygen (20% O2) with or without 1 mM WR-1065; or low oxygen conditions (3% O2). HIF-1a and HIF-2a were detected by Western blot (Ku80
used as internal control). (B) Amifostine treatment does not lead to the induction of HIF-1 target genes. Cells were treated with WR-1065, in the
presence of AG, for 16 h or exposed to low oxygen conditions (3% O2) for 16 h. Total mRNA were isolated and the expression of HK-2 and
GLUT-1 genes were assessed by quantitative polymerase chain reaction Q-PCR); b-actin served as internal control. (C/D) Amifostine-mediated
VEGF-A upregulation is not impaired by a HIF-1a.shRNA (small hairpin RNA). (C) Western blot analysis of HIF-1a protein levels in MCF7 cells
transduced with RFP.shRNA (control) and HIF-1a.shRNA constructions. Cells were treated with 1 mM WR-1065 for 16 h (upper panel, “+”), or
exposed to low oxygen conditions (3% O2) or classical conditions (20% O2) for 6 h (lower panel). Proteins were analysed by Western blot using
specific antibodies for HIF-1a and for Ku80 (control of loading). (D) VEGF-A mRNA expression was assessed by Q-PCR in MCF7 cells transduced
with lentiviral constructs expressing either HIF-1a.shRNA or control RFP.shRNA (grey and white bars, respectively). Cells were incubated for 16 h
in the presence of WR-1065 or subjected to low oxygen conditions (3% O2). Expression of global VEGF-A mRNA in HIF-1a.shRNA-expressing cells
was determined by Q-PCR and expressed in fold-change relative to untransduced-cells left untreated. Significant expression changes were
determined by Student’s paired tests.
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increasing periods of time with 2 mM WR-1065 or 10 μg/mL Tunicamycin (Tun) in complete culture medium. Proteins and mRNA were
collected at several time points, and protein and gene expression were assessed by Western-Blot and polymerase chain reaction (PCR) analyses.
(A) Amifostine differentially up-regulates BIP, EDEM, GADD34 and CHOP genes in MCF7 cells. Quantitative-PCR profiles of BIP, EDEM, GADD34 and
CHOP genes, in MCF7 cells treated with WR-1065. Results were normalized using a-tubulin mRNA and expressed as ratios between the treated
[aminoguanidine (AG)+WR1065] and untreated (AG alone) conditions. The time zero of the experiment is set to 1. (B) Amifostine triggers eIF2a
phosphorylation in MCF7 cells. Western-blot analysis of total (Tot.eIF2a) and phosphorylated eIF2a (P-eIF2a) in MCF7 cells treated or not with 2
mM WR-1065. A 1 h treatment with 2 mM dithiothreitol was used as a positive control for eIF2a phosphorylation. Total protein extracts were
resolved on 12% SDS-PAGE, and protein levels were assessed using specific anti-eIF2a and anti-P-eIF2a antibodies. (C/D) Amifostine-induced
vascular endothelial growth factor A (VEGF-A) up-regulation requires activating transcription factor 4 (ATF4). MCF7 cells were transduced with a
small interfering (si)RNA directed against ATF4 (SiATF4, white bars) or with the same siRNA mutated in three nucleotides (SiMUT, grey bars), used
as control;. Transduced cells were treated for 24 h with AG alone (CTL) or in combination with 2 mM WR-1065. (C) ATF4 gene expression was
assessed by real-time reverse polymerase chain reaction (RT-PCR). (D) VEGF-A gene expression was assessed by real-time RT-PCR. ATF4 and
VEGF-A mRNA expression levels in amifostine-treated cells are expressed as fold changes to the control condition (AG alone), which were set to
1 for SiATF4 and SiMUT. Error bars correspond to standard deviations for each triplicate determination.
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dent pathway. Indeed, eIF2a was transiently phosphory-
lated after 2 h of treatment with WR-1065 (Figure 3B).
Consistently, blockade of ATF4 expression using a
siRNA strategy (Figure 3C) led to the inhibition of WR-
1065-induced VEGF-A expression, both at the mRNA
(80 to 90%, Figure 3D) and at the protein (50%, Addi-
tional File 3, Figure S3) levels. Overall, these results
indicate that ATF4 is required for amifostine-induced
VEGF-A up-regulation.
Amifostine-treated tumour cells mediated a paracrine
stimulation of EC
The increased release of VEGF-A by WR-1065-treated
tumour cells suggests a possible paracrine activity
mediated by the chemoprotectant amifostine on EC. In
order to confirm this, MCF7 cells were stimulated by
WR-1065 for 48 h and cell-conditioned media were
then tested for their ability to stimulate starved EC
using the MTT metabolic assay (Figure 4). WR-1065
indeed stimulated the release by tumour cells of a
diffusible EC growth factor that is able to significantly
increase the metabolic activity of EC cells (34%). This
stimulatory effect was partly inhibited (20%) by 1 μgo f
a VEGF-A neutralizing antibody, indicating that VEGF-
A produced by tumour cells plays a significant role in
this endothelial cell stimulation. Increasing the concen-
trations of the neutralizing VEGF-A antibody (from 0.03
to 1 μg) failed to produce a higher inhibitory effect,
whereas it completely abolished the effect of recombi-
nant VEGF-A. These results suggest that additional EC
growth factors may also contribute to the tumour-
mediated EC stimulation.
Inhibitory effects of amifostine on EC
The stimulatory paracrine effect of VEGF-A on EC
should predict stimulation of the neovascularization pro-
cess. However, since EC cells are the first cellular target
of amifostine in vivo, we also considered the effect of
amifostine directly on EC proliferation, migration and
differentiation into tubular-like structures. Thus,
H U V E Cw e r eg r o w ni nt h ep r e s e n c eo fV E G F - Aw i t h
Figure 4 Amifostine induces a paracrine stimulatory effect on endothelial cells (ECs).M C F 7c e l l sw e r eg r o w nt os u b c o n f l u e n c ea n d
incubated for 48 h in the presence or absence of 1 mM WR-1065. Conditioned media (CM) were then collected and dialyzed to remove WR-
1065. Cells were counted. Vascular endothelial growth factor A (VEGF-A) neutralizing antibody (1 μg/mL) were added or not to CM from WR-
1065-treated (WR-1065) or AG-treated control cells (CTL). These control cells were supplemented (CTL+VEGF) or not (CTL) with 10 ng/mL VEGF-A.
CM were added to HUVEC that have previously been starved in fetal bovine serum-free Dulbecco’s modified eagle medium (see Materials and
Methods section). Human umbilcal vein EC metabolic activity was measured using the Wst1 assay over a 14 h incubation time in the presence
of CM. Results are expressed as means ± standard deviation of the OD (Optical Density) measured at 440 nm from six independent cell culture
wells. Significant changes in OD, as determined by Student paired tests, are depicted on the histogram (* P < 0.05; ** P < 0.01).
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Page 8 of 14various concentrations of WR-2721. This allows a pro-
gressive release of WR-1065 throughout the duration of
treatment. Compared to untreated cells, WR-2721-trea-
ted cells have a significantly reduced cell growth and the
effect was dose-dependent (Figure 5A, ED50 ~0 . 5m M
after a 2-day incubation, see insert). This growth-inhibi-
tion was also observed using bovine EC of aortic origin
(BAE; Additional File 4, Figure S4A). The inhibitory
activity may result from a p53-dependent cell cycle
arrest in G1 as previously described ([10], see also Addi-
tional File 4, Figure S5). We then determined whether
amifostine may influence VEGF-A-induced EC migra-
t i o n .H U V E Cw e r et r e a t e d ,o rn o t ,w i t hV E G F - Ai nt h e
presence of increasing concentrations of WR-1065 and
allowed to migrate for 7 h. Figure 5B shows that WR-
1065 inhibits the VEGF-A-induced migration of EC in a
dose dependent manner. Again, similar result was
obtained using BAE cells (Additional File 4, Figure S4B).
Finally, we analysed the effects of amifostine treatment
on the in vitro formation of capillary-like structures by
EC. For this, HUVEC were cultured on Matrigel and
treated or not with VEGF-A and/or WR-1065. Figure
5C shows that treatment with WR-1065 completely
abolished the VEGF-A induced capillary formation. WR-
1065 alone had no significant effect, neither on migra-
tion, nor on tubule formation on serum-starved EC
(data not shown). Taken together these results indicate
that amifostine strongly impairs the activity of VEGF-A
on EC proliferation, migration and differentiation, mak-
ing them unresponsive to a potential paracrine effect
mediated by this growth factor.
Amifostine treatment impairs VEGF-A binding and
signalling in EC
In order to understand how amifostine does inhibit EC
response to VEGF-A, HUVEC were treated with WR-
1065 and the level of VEGF receptor 2 (VEGFR-2) was
measured by Western blot. Figure 6A shows that from 2
h to 24 h of incubation with WR-1065, VEGFR-2 pro-
tein expression is decreased by ~50% in treated cells as
compared to untreated cells. This down-regulation
occurs most likely at different levels including the tran-
scriptional level, since VEGFR-2 mRNA is transiently
down-regulated in these conditions (Additional File 5,
Figure S6). Scatchard analysis of 125I-VEGF-A binding
to its receptors on HUVEC was also performed. In
agreement with the decrease in VEGFR-2 protein
expression, the binding data of three independent
experiment consistently showed a ~25% to 30% decrease
in the number of VEGF-A molecules associated to high
affinity receptors after a 12 h pre-treatment with 1 mM
of WR1065 (Figure 6B). The apparent dissociation con-
stant was not significantly modified in these conditions,
which indicates that the decrease in VEGF-A binding is
due in part to the down regulation of its receptors. In
addition to this long-term effect of amifostine on
VEGFR2 expression and availability at the cell membrane,
immediate phosphorylation of p42/p44 kinase in HUVEC
in response to VEGF-A was strongly reduced (~64%)
when applied in the presence of WR1065 (Figure 6C).
This was also observed to a greater extent in BAE cells
(Additional File 4, Figure S4C). Together, these results
indicate that WR-1065 has both immediate and long-
term effects on the EC responses by impairing VEGF-A
binding and signalling.
Discussion
O u ri n v e s t i g a t i o n ss h o w e dt h a tt h er a d i o -a n dc h e m o -
protective drug amifostine is a potent inducer of VEGF-
A expression, acting both at the mRNA and protein
levels in several human cancer cell lines. Accumulation
of VEGF-A mRNA was detected at concentrations of
the drug (0.5 - 2 mM) that correspond to those mea-
sured in most tissues of treated rats and monkeys 10 to
30 min after an injection of a single protective dose
[8,42]. This suggests that VEGF-A up-regulation may
also occur along clinical cancer treatments of patients
with the cytoprotective drug and questions about the
possible angiogenic side effects of such treatments.
To date, the effects of amifostine on angiogenesis were
still poorly studied and results were found somewhat
controversial [32]. In addition, little is known of the
effects of amifostine on VEGF-A expression. Therefore,
the potential impact of amifostine on angiogenesis has
to be clarified, in particular in relation to the VEGF-A
expression. A study from Koukourakis showed that HIF-
1a was stabilized both in vitro and in vivo by high con-
centrations of amifostine (8 mM) [13]. Since HIF-1a
acts as a pro-angiogenic transcription factor and
increases VEGF-A expression [14], we first thought that
it was responsible for VEGF-A up-regulation in cancer
cells exposed to amifostine in our experiments. How-
ever, using concentrations of amifostine consistent with
the clinical approach, we failed to observe in our cell
models any accumulation of either HIF-1a or HIF-2a
proteins in response to the drug treatment. Our data
clearly show that HIF-1a activity is not involved in
VEGF-A up-regulation under amifostine treatment at
clinical doses, which led us to consider alternative
VEGF-A stimulatory pathways.
Amifostine is a disulphide reducing agent that can
generate redox stress in cells [12] and other thiol-con-
taining compounds are known to affect protein folding
and to activate the UPR [24]. We therefore investigated
whether UPR was activated in response to amifostine
and whether this could lead to VEGF-A mRNA expres-
sion as previously reported [21]. The increased expres-
sion of several genes considered to be hallmarks of the
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Page 9 of 14Figure 5 Amifostine inhibits human umbilcal vein endothelial cells (HUVEC) proliferation and vascular endothelial growth factor A
(VEGF-A)-induced migration and differentiation. (A) Amifostine inhibits HUVEC proliferation. HUVEC growing in endothelial growth medium-2
supplemented with 0, 0.25, 0.5, 1 or 2 mM of WR-2721 were counted for 3 days. The insert shows the inhibition of cell proliferation after 2 days
of treatment, in percentage of untreated cells. (B) Amifostine inhibits VEGF-A dependant HUVEC migration. A Transwell migration assay was used.
HUVEC were seeded in upper compartments and incubated in Dulbecco’s modified eagle medium containing (DMEM) 0.5% fetal bovine serum
(FBS), 0.1% bovine serum albumine and increasing concentrations of WR-1065. 10 ng/mL VEGF-A were, or were not, added in the lower
compartment and cells were allowed to migrate for 7 h. Cells that migrated were fixed, stained and quantified. Left panel: quantification of
VEGF-A-dependent HUVEC migration (% of the migration versus control untreated cells). Significant changes were determined by Student paired
tests (*P < 0.05; **P < 0.01). Right panel: corresponding photomicrographs of HUVEC. (C) Amifostine inhibits VEGF-A induced capillary-like
structures formation. HUVEC were seeded on GFR-Matrigel. After a 1 h incubation in 0.5% FBS-containing DMEM to allow cell adhesion, cells
were treated with WR-1065 for 3 h, in the presence or absence of 10 ng/mL VEGF-A. Total tubule length was determined using NIS image
analysis software. Left panel: quantification of total tubule length in the different experimental conditions. Results are expressed as percentages
of the average tubule length in the control condition, set to 100%. The control condition corresponds to absence of both VEGF-A and WR-1065.
Significant changes, were determined by Student paired tests (*P < 0.05; **P < 0.01). Right panel: phase-contrast microphotographs of tubule
networks formed by HUVEC, at a 200-fold magnification.
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Page 10 of 14UPR pathways (BIP, EDEM, CHOP and GADD34)f o l -
lowing amifostine treatment suggests that amifostine did
activate the UPR signalling pathways. However, the low
increase in BIP and EDEM mRNA expression, which
usually relies upon IRE1- and ATF6-dependant path-
ways [44,45], suggests that these pathways were not fully
activated in response to amifostine. In addition, there
was no detectable XBP1 splicing in treated cells, sug-
gesting that IRE1 is not induced by amifostine and thus
does not significantly contribute to VEGF-A up-
regulation.
T h es t r o n gi n c r e a s ei nCHOP and GADD34 mRNA
expression could be linked to either PERK activation or
to the GCN2-dependant pathway, both leading to eIF2a
phosphorylation, inhibition of cap-dependant translation
and activation of the ATF4 transcription factor [46,47].
Interestingly, homocysteine, a compound related to ami-
fostine by the presence of its thiol function, has been
shown to induce ATF4 transcriptional activity, leading
to increased expression of VEGF-A [24]. Consistently,
we observed a transient eIF2a phosphorylation in
response to amifostine treatment, which suggests the
involvement of ATF4 for VEGF-A expression. Indeed,
abolition of ATF4 expression (~95%) using siRNA strat-
egy clearly demonstrated that VEGF-A up-regulation
upon exposure to amifostine strongly relies on ATF4.
However, other pathways may also contribute to the
amifostine-mediated effects on VEGF-A expression such
as the c-jun N terminal kinase pathway (JNK). JNK is a
known intermediate of VEGF-A mRNA and protein up-
regulation [48,49] and we previously showed that this
pathway is also activated by amifostine [11]. Consis-
tently, the chemical JNK inhibitor SP-600125 did reduce
the extent of amifostine-induced VEGF-A activation by
1.4 fold (not shown). Interestingly, JNK activation is also
linked to the UPR downstream of the ER-stress-induced
activation of IRE1a, independently of its endoribonu-
clease activity [50], and IRE1a is itself involved in the
up-regulation of VEGF-A in cancer cells undergoing
ischemia [21]. Collectively, these data suggest that JNK
might also synergize with ATF4 to up-regulate VEGF-A
expression in response to amifostine.
The potential pro-angiogenic effect of amifostine in
cancer cells may not be limited to the activation of
VEGF-A expression. Experiments using VEGF-A block-
ing antibodies indicated that, in addition to this growth
factor, treated tumour cells may also secrete other
endothelial cell growth promoting factors. EGF or IL8
are possible candidates for this effect stand, and their
expressions were up-regulated (up to 13- and 5.2-fold,
respectively) in MCF7 cells upon stimulation by amifos-
tine, as determined using transcriptome analysis (not
shown). Amifostine is currently used as a cytoprotector
in therapeutic treatment, either as a single dose
Figure 6 Amifostine inhibits vascular endothelial growth factor
(VEGF)R2 expression, VEGF-A binding and signalling in human
umbilcal vein endothelial cells (HUVEC). A Amifostine treatment
inhibits VEGFR-2 protein expression in HUVEC. After a 24 h-starvation,
subconfluent HUVEC were incubated in the presence or absence of 1
mM WR-1065 for indicated period of time and total proteins were
collected in an RIPA buffer and resolved on a 7.5% acrylamide SDS-PAGE
gel. Proteins were blotted onto a nitrocellulose membrane and probed
with a mouse monoclonal antibody against VEGFR-2. Equal loading of
proteins was confirmed by b-actin detection. VEGFR-2 migrated at gel
positions corresponding to the 150- and 200-kDa forms, as already
reported in HUVEC. The blot is representative of three independent
experiments. (B) Amifostine treatment impairs VEGF-A binding on
HUVEC. HUVEC monolayers (7000 cells/cm2) were allowed to grow for 3
days and then incubated for 12 h in the absence or presence of 1 mM
WR-1065. Cells were then exposed to increasing concentrations of 125I-
labelled VEGF-A for 2 h at 4°C. The amount of specifically bound
iodinated VEGF-A was then determined. Insert represents Scatchard plot
corresponding to the saturation curves. The experiment was carried out
three times with similar results. (C) Amifostine treatment impairs
mitogen activated protein kiinase signalling in HUVEC. Subconfluent
HUVEC in serum-free Dulbecco’s modified eagle medium were treated
with 10 ng/mL VEGF-A for 10 min, alone or together with 1 mM WR-
1065. Cytoplasmic proteins were then collected and were resolved on
15% SDS-PAGE. Total (phosphorylated and unphosphorylated) p42/p44
proteins as well as the phosphorylated proteins (P-p42/P-p44) were
probed using specific antibodies. Signal was assessed by quantification
of chemoluminescence, and ratios between signal intensities of P-p42/
P-p44 and total p42/p44 are given beneath the gel. They were
normalized to the ratio obtained for untreated cells (VEGF -, WR-1065-),
which is set to 1.
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Page 11 of 14treatment for cancer therapies or in long-term chronic
delivery in the treatment of myelodysplasic syndromes
[4,7,51]. Side-induction of VEGF-A, or of any other pro-
angiogenic factors, by cancer cells during these treat-
ments may have detrimental effects on the therapeutical
purposes. Therefore, it was necessary to investigate
whether amifostine could develop secondary effects
when applied directly on EC.
EC are subjected to the highest concentrations of ami-
fostine following its intravenous administration. Com-
paratively, cancer cells accumulate lower concentrations
of the drug, as it is known to hardly penetrate tumour
masses [4,8]. Since we had previously found an anti-pro-
liferative effect of amifostine on normal and cancer cells
([10,52] and unpublished data), we considered the possi-
bility that amifostine also impedes EC proliferation,
which could overcome the tumour-mediated pro-angio-
genic effect. In fact, as reported here, each of the
endothelial cell responses to VEGF-A was strongly
inhibited by amifostine treatment, therefore suggesting
that EC were indeed made unresponsive to tumour-
mediated VEGF-A stimulation by clinical doses of the
drug.
The origin of EC desensitization in response to ami-
fostine treatment was then considered. The EC prolif-
eration arrest should be considered as the consequence
of a p53 dependent-cell cycle arrest in G1, as already
observed in various cell types ([10,52] and unpublished
data). In addition, we showed that amifostine plays a
role in EC capacity to respond to VEGF-A. An immedi-
ate impairment of intracellular signalling was observed
downstream to this interaction, as indicated by the 50%
decrease of the VEGF-A-induced phosphorylation of the
ERK kinases in the presence of amifostine. As ROS are
essential second messengers in EC [26,27], this inhibi-
tory effect may depends on the ROS scavenging proper-
ties of the drug, leading to the blockade of the
downstream signalling of VEGFR-2.
In addition to this immediate effect, we observed a
long-term effect of amifostine on the capacity of EC to
bind VEGF-A. This was shown by a significant decrease
in VEGF-A binding to its specific cell-surface receptors
after 12 h of amifostine treatment. This long-term effect
depends on the down-regulation of VEGFR-2 protein
expression at the plasma membrane. This down regula-
tion probably results from a combination of complex
intra- and extra-cellular redox effects due to the free
thiol group of WR-1065. Part of these effects may occur
at the transcriptional level by inactivating redox sensitive
transcription factors involved in VEGF-R2 expression as
it does for p53 and NFKappa B [10,12,53]. An additional
effect may occur at the translational level through the
global inhibition of translation due to eIF2a phosphory-
lation in response to treatment [46,47]. In addition,
although no modulation of VEGF-A affinity to its recep-
tors was observed in our experiments, we cannot com-
pletely rule out the possibility of an additional direct
effect of the thiol group of amifostine on VEGF-A bind-
ing to its receptors. Indeed, VEGF-A exists as a disul-
phide-bond functional dimer. VEGF-A dimerization,
which is essential for its biological activity, may be
impaired under reducing conditions [54]. Moreover,
VEGFR-2 ligand binding sites are located within Ig-like
extracellular domains that may also be sensitive to
redox conditions [17]. By potentially modifying the
structure of the two partners, amifostine may inhibit the
interaction between VEGF-A and VEGF-R2, therefore
inducing a down-regulation of VEGF-R2 expression
[55]. Finally, activation of the stress induced kinase JNK
by amifostine may trigger specific phosphorylation of
VEGF-R2 receptor that could lead to its internalization
and degradation as it has already been described for epi-
dermal growth factor receptor [56]. Thus, several char-
acteristics of amifostine likely contribute to render
endothelial cell unresponsive to external VEGF-A
stimuli.
Conclusion
This study shows that amifostine exerts a complex dual
role on VEGF-A biology. On the one hand, the drug
activates VEGF-A production by cancer cells. On the
other hand, it blocks the VEGF-A responsiveness of EC.
This latter effect is due to both an immediate effect on
VEGF-A binding and/or downstream signalling through
VEGFR-2; and to a long-term inhibition of the VEGFR-
2 expression at the cell membrane. Since amifostine is
believed to enter normal cells better than cancer cells
in vivo [4,8], and since it is often administered intrave-
nously, its effects should be prominent on EC. This sug-
gests that the drug may act primarily as an anti-angiogenic
compound on EC, in addition to its well-characterized
protective effects. In vivo experiments are on the way to
determine whether the use of amifostine does modify the
tumour vasculature and/or facilitate the penetration of
classical anti-cancer drugs into tumour masses [57].
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Page 12 of 14Additional file 1: Table S1. Sequences of the primer used either for
semi quantitative polymerase chain reaction (Q-PCR) or for real time Q-
PCR(*). Primers for activating transcription factor 4 were as described by
Namba et al. [37]. Primers for GADD34, CHOP, EDEM and BIP were as
previously described [21]. All primers were obtained from Proligo (Paris,
France).
Additional file 2: Figure S1. Amifostine does not induce hypoxia-
inducible factor (HIF)-1a nuclear accumulation. MCF7 grown to 70%
confluence on Lab-Tek chamber slides were treated for 6 h with 4 mM
aminoguanidine alone (O2 20%) or in combination with 1 mM amifostine
(WR-1065), or submitted to low oxygen conditions for 6 h (O2 3%).
Detection of HIF-1a was achieved by incubation with an anti-human
HIF-1a monoclonal antibody. Nuclei were stained by Hoechst 33342.
Fluorescence labelling was observed by confocal microscopy, right panel
shows the two merged pictures obtained.
Additional file 3: (Figure S2) Amifostine does not induce XBP1
mRNA splicing and (Figure S3) activating transcription factor 4
(AFT4) is required for increased vascular endothelial growth factor
A (VEGF-A) protein secretion in response to amifostine. (Figure S2)
MCF7 and U87 cells were grown up to 70% confluence in 10 cm-dishes.
Cells were then treated for increasing periods of time with 2 mM WR-
1065 or 10 μg/mL Tunicamycin (Tun) in complete culture medium.
mRNA were collected at several time points, and mRNA splicing and
expression were assessed by reverse transcriptase-polymerase chain
reaction analysis. Gel electrophoresis patterns of expression of unspliced
(XBP1u) and spliced (XBP1s) XBP1 transcripts, in MCF7 cells and U87 cells.
(Figure S3) MCF7 cells were transduced with a small interfering (si)RNA
directed against ATF4 (SiATF4, white bars) or with the same siRNA
mutated in three nucleotides (SiMUT, grey bars), used as control.
Transduced cells were treated for 24 h with aminoguanidine alone (CTL)
or in combination with 2 mM WR-1065. VEGF-A protein expression was
quantified by ELISA from cell supernatants. Error bars correspond to
standard deviations for each triplicate determination. See Additional File
2 for materials and methods for supplementary figures.
Additional file 4: Figures S4 and S5. (Figure S4) Amifostine inhibits the
proliferation and migration of BAE cells, as well as VEGF-A signalling in
those cells. Figure S5. Amifostine inhibits cell cycle progression of BCE in
G1. See additional file 2 for materials and methods for supplementary
figures.
Additional file 5: Figure S6. Amifostine treatment decreases vascular
endothelial growth factor-R2 mRNA expression or stability. After a 24 h-
starvation, subconfluent human umbilcal vein endothelial cells were
incubated in the presence or absence of 1 mM WR1065 and total mRNA
were collected at the indicated time points. Reverse transcription and
real time quantitative polymerase chain reaction was performed as
previously described (Methods). Results are shown in fold induction as
compared to control untreated cells. They were normalized to a-tubulin
and correspond to the mean values ± standard deviation of triplicates
from three independent experiments. See Additional File 2 for materials
and methods for supplementary figures.
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